高瓴重仓领域——港股生物医药股全线下跌

Gelonghui
2021.08.12 07:26
腾盛博药-B 跌超 13%，诺诚健华-B 跌超 11%，康希诺生物、泰格医药和荣昌生物-B 跌超 7%，加科思-B、百济神州、康诺亚-B 跌超 6%，科济药业-B 跌 5%，方达控股、沛嘉医疗-B 跌超 4%，启明医疗-B、药明康德和药明巨诺-B 跌超 3%。生物医药是高瓴的重仓领域，有数据显示，高瓴目前在全球医疗健康产业中已投资 200 余家企业，其中，国内企业 100 余家。注：2020 年 9 月 1 日，在 2020 香港交易所生物科技峰会中，高瓴创始人张磊曾表示，高瓴在生物医药行业投资了 1200 亿元。
Source: Gelonghui The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.